David E. Shaw

D. E. Shaw Research — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

101h-index60.6kcitations654works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fibroblast Growth Factor Research(95), Eosinophilic Disorders and Syndromes(75), Protein Structure and Dynamics(70), PI3K/AKT/mTOR signaling in cancer(49), Enzyme Structure and Function(35)

Publications652 total

Supplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Appendix S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
810 Reducing the age at first event in infants with a positive cystic fibrosis newborn screen in Arkansas: a quality improvement initiative
Journal of Cystic Fibrosis·2025
Validation of a model of rheumatoid arthritis using mice reconstituted with patient peripheral blood mononuclear cells
Disease Models & Mechanisms·2025Open Access
An RNA-mediated DNA melting mechanism for CRISPR-Cas9
2025Open Access
Optimising Wastewater Sample Processing for Multiple Pathogen Detection
International Journal of Infectious Diseases·2025Open Access
Ensemble cryo-EM reveals conformational states of the nsp13 helicase replication-transcription complex
EMPIAR dataset·2025Open Access
282 (PB270): Impact of Implant Location on In Vivo Therapeutic Response and Immune Modulation in the MC38-luc Mouse Colon Carcinoma Model
European Journal of Cancer·2024
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
page 1 of 33Next →

Frequent Co-authors

Ron O. Dror(31), Yibing Shan(16), Michael P. Eastwood(15), Stefano Piana(12), John L. Klepeis(9), Daniel H. Arlow(9), David W. Borhani(9), Kresten Lindorff‐Larsen(8), Paul Maragakis(8), John K. Salmon(8), Huafeng Xu(7), Mark A. Moraes(7), Albert C. Pan(7), K. J. Bowers(5), J.P. Grossman(5), Brian K. Kobilka(5), Douglas J. Ierardi(5), Morten Ø. Jensen(5), John Kuriyan(5), Joseph A. Bank(4)